

Vax genes ventralize the embryonic eye

Stina H. Mui,^{1,2,4} Jin Woo Kim,^{1,4} Greg Lemke,^{1,5} and Stefano Bertuzzi³

¹Molecular Neurobiology Laboratory, The Salk Institute La Jolla, California 92037, USA; ²Department of Neurosciences, University of California, San Diego, La Jolla, California 92039, USA; ³Dulbecco Telethon Institute, National Research Council-Institute of Biomedical Technologies, 20090 Segrate (Milan), Italy

The vertebrate retina and optic nerve are strikingly different in terms of their size, organization, and cellular diversity, yet these two structures develop from the same embryonic neuroepithelium. Precursor cells in the most ventral domain of this epithelium give rise only to the astrocytes of the optic nerve, whereas immediately adjacent, more dorsal precursors give rise to the myriad cell types of the retina. We provide genetic evidence that two closely related, ventrally expressed homeodomain proteins—Vax1 and Vax2—control this neuroepithelial segregation. In the absence of both proteins, we find that the optic nerve is transformed in its entirety into fully differentiated retina. We demonstrate that this transformation results from the loss of ventralizing activity in the developing eye field, and that ventralization is mediated, at least in part, via Vax repression of the Pax6 gene, a potent inducer of retinal development.

[*Keywords:* Retina; homeobox; Pax6; development; mouse]

Received October 27, 2004; revised version accepted April 6, 2005.

Developmental boundaries within the embryonic neuroepithelium frequently establish and constrain the differentiation potential of neural stem cells, and this is dramatically so for the developing eye. The evaginated neuroepithelium that gives rise to the eye—the optic vesicle—buds from the ventral diencephalon of the embryonic brain (Chow and Lang 2001). During this process, a sharp dorsoventral territorialization occurs, with the optic disk separating the ventral optic stalk from the more dorsally positioned presumptive retina. The optic stalk, which is apposed to the midline source of the ventralizing morphogen sonic hedgehog (Shh), develops into the optic nerve (Marti and Bovolenta 2002). The presumptive retina, which is further removed from, and receives a lower dose of this morphogen, develops into the neural retina (NR) proper (Chow and Lang 2001; Figs. 1A,B, 2A–C). These dramatic differences in tissue morphogenesis are mirrored in neuroepithelial cell differentiation; cells that are segregated into the ventral optic stalk undergo limited rounds of cell division and differentiate into only a single cell type—optic nerve astrocytes (Mi and Barres 1999). In marked contrast, adjacent cells that are segregated into the presumptive NR become retinal progenitor cells (RPCs), which undergo many more rounds of cell division and differentiate asynchronously into diverse cell types, including retinal ganglion cells (RGCs), photoreceptors, amacrine cells, bipolar cells, horizontal cells, and Müller glia (Livesey and Cepko 2001).

Although dosage manipulations of Shh have demonstrated that the levels of this morphogen are critical to dorsal–ventral patterning of the optic vesicle (Macdonald et al. 1995; Chiang et al. 1996; Ohkubo et al. 2002), the intracellular effectors of Shh in the eye field have remained elusive. We have previously reported on two closely related transcription factors—encoded by the *ventral anterior homeobox* (*Vax*) genes 1 and 2—whose expression domains and loss-of-function phenotypes in the mouse are consistent with their functioning as such effectors (Bertuzzi et al. 1999; Mui et al. 2002). We now describe the remarkable phenotypes seen in the developing eye field of *Vax1/Vax2* double-mutant embryos, in which the optic nerve is transformed into retina. We demonstrate that Vax1 and Vax2 normally act in concert to ventralize this field, and that they achieve this through repression of the *Pax6* gene. The Vax proteins thereby drive the development of a ventral structure, the optic nerve, by inhibiting the development of its more dorsal neighbor.

Results

Genetic interaction between Vax1 and Vax2

From approximately embryonic day 13.5 (E13.5) onward, the mouse *Vax1* and *Vax2* genes exhibit nonoverlapping patterns of expression (Bertuzzi et al. 1999; Hallonet et al. 1999; Barbieri et al. 2002; Mui et al. 2002); *Vax1* is expressed in the optic stalk (Fig. 1C), while *Vax2* is expressed in the developing neural retina, where it exhibits both a steep high-ventral-to-low-dorsal gradient and a shallower high-nasal-to-low-temporal gradient (Fig. 1D; Mui et al. 2002). These sharply segregated E13.5 patterns


⁴These two authors contributed equally to this work.

⁵Corresponding author.

E-MAIL lemke@salk.edu; FAX (858) 455-6138.

Article and publication are at <http://www.genesdev.org/cgi/doi/10.1101/gad.1276605>.

Figure 1. (A) Schematic dorsal–ventral (DV) section of the mouse neuroepithelium as it bulges out from the ventral diencephalon at E9.5 to form the optic vesicle. Sonic hedgehog (Shh), expressed at the ventral midline, has patterned this tissue along the DV axis by this time, such that structures closest to Shh are most ventral. pvOS, pNR, pRPE, and pdOS are presumptive ventral optic stalk (red), neural retina (green), retinal pigment epithelium (yellow), and dorsal optic stalk (gray), respectively. Graded expression of the *Vax1* and *Vax2* genes within these tissue anlagen is indicated. (B) A schematic DV section similar to that in A, at E10.5, after the optic vesicle has invaginated to form the optic cup. (C–F) *Vax1* (C), *Vax2* (D), *Pax2* (E), and *Pax6* (F) mRNA in the developing eye at E13.5 as revealed by in situ hybridization. *Vax1* and *Pax2* mRNAs are both confined to the optic stalk (OS) and optic disk (OD), and are excluded from the neural retina (NR). In contrast, *Vax2* and *Pax6* mRNAs are confined to the retina at this same time, with *Vax2* exhibiting a high-ventral-to-low-dorsal expression gradient (D). (G–J) Whole-mount images of wild-type, *Vax* single-mutant, and *Vax* double-mutant embryos at E13.5. The *Vax1* and *Vax2* genes exhibit strong genetic interaction, as revealed by the presence of coloboma in single and double mouse mutants. The pigmented RPE completely encompasses the eye in wild-type (wt) E13.5 embryos (G), but all *Vax1* mutant embryos display a coloboma (arrowhead) in the ventral retina at this same time (H). A subset of *Vax2* mutants exhibit a very small coloboma at E13.5 (I), but all double mutants (dko) carry an extreme coloboma that occludes RPE from the ventral half of the eye (J). (K,L) Whole eyes in wild-type and double mutants, respectively, at birth (P0). (L) During late embryogenesis, proliferation of ectopic retina in the double mutants is so pronounced (see below) that by P0, RPE is found only in a small strip of dorsal tissue that extends to the midline of the brain. (K) RPE surrounds the wild-type eye up to its junction with the optic nerve (ON). Bars in C (for C–F), G (for G–J), K, and L all represent 100 μ m.



of expression for *Vax1* and *Vax2* are similar to those seen at the same time for mRNAs encoding the paired homeodomain transcription factors *Pax2* (Fig. 1E) and *Pax6* (Fig. 1F), respectively. We were therefore surprised to observe a strong genetic interaction between *Vax1* and *Vax2* in mice in which both genes are inactivated. This interaction is apparent at multiple levels, but is initially most obvious in the appearance of retinal coloboma, a failure of the optic fissure to close ventrally and form the optic disk, the boundary between the optic nerve and the retina (Fig. 1G–J). Coloboma is not observed in E13.5 wild-type embryos (Fig. 1G), is fully penetrant, but of moderate severity in *Vax1*^{-/-} mutants (Fig. 1H), and is both rare in occurrence and mild in *Vax2*^{-/-} mice (Fig. 1I). In marked contrast, it is fully penetrant and notably severe in *Vax1*^{-/-}*Vax2*^{-/-} double mutants (Fig. 1J). By the time of birth, the double mutants display a grotesquely configured eye, in which the boundary between retina and optic nerve is absent, and both retinal pigment epithelium (RPE) and neural retina (NR) are found throughout the territory of the optic nerve (Fig. 1K,L).

Vax genes act at the midpoint of mouse embryogenesis

Most of the previously described mouse *Vax1* and *Vax2* single-mutant phenotypes have been analyzed from late embryogenesis through the first two post-natal weeks (Bertuzzi et al. 1999; Hallonet et al. 1999; Barbieri et al. 2002; Mui et al. 2002). However, we find that these phenotypes actually reflect *Vax* gene activity during a much

earlier, relatively narrow window of time, from approximately E9.5 to E11.5, when the two genes are, in fact, coexpressed. During this time, mouse *Vax1* extends from the ventral optic stalk into the ventral retina, and conversely, mouse *Vax2* extends from the ventral retina into the ventral optic stalk (Ohsaki et al. 1999). At E9.5, the developing eye has progressed to the optic vesicle stage, and has already been patterned along the dorsal–ventral axis through the action of sonic hedgehog (Figs. 1A, 2A). Invagination of the optic vesicle occurs over the ensuing day, and leads to the formation of the optic cup by E10.5 (Figs. 1B, 2B). At this stage, the diminishing expression of *Vax1* mRNA in the ventral retina is also graded along the nasal–temporal axis—from high in the ventral nasal retina to low in the ventral temporal retina (Fig. 2D–F). This *Vax1* gradient is therefore similar to the high-nasal-to-low-temporal gradient of *Vax2* mRNA in the ventral retina, which, unlike *Vax1*, persists into late embryogenesis (Mui et al. 2002). By E11.5, the general configuration of what will be the mature eye is apparent, with the RPE having extended ventrally to surround the eye, and the entirety of the *Vax1*⁺ ventral optic stalk having invaginated into the interior of the developing optic nerve (Fig. 2C). The evolving *Vax1* and *Vax2* expression patterns from E9.5 to E11.5 are schematized in Figure 2G and I.

The importance of the overlapping expression of *Vax1* and *Vax2* from E9.5 to E11.5 is revealed by the appearance of double-mutant phenotypes, which first develop at this time, and are evident in an increasingly pronounced alteration in *Pax* gene expression (Fig. 3). At




Figure 2. Overlapping expression of the *Vax1* and *Vax2* genes from E9.5 to E11.5. (A–C) Schematic three-dimensional view of eye development at E9.5, E10.5, and E11.5 in the mouse (lens not shown). Red, green, yellow, and gray regions of the neuroepithelium indicate ventral optic stalk, neural retina, RPE, and dorsal optic stalk, respectively. (D–F) Three DV sections—nasal (D), central (E), and temporal (F)—of the E10.5 optic vesicle, hybridized with a *Vax1* probe. *Vax1* mRNA is apparent in the optic stalk throughout, and in the ventral nasal (bracketed in D) but not ventral temporal E10.5 retina. (G–I) Schematic representation of the expression domains of the mRNAs encoding *Vax1* (purple) and *Vax2* (blue), at E9.5, E10.5, and E11.5. Expression of the two genes is extensively overlapping at E9.5, less so at E10.5, and very much less so at E11.5. By E12.5, the expression of *Vax1* and *Vax2* no longer overlaps. Bar in D (for D–F) represents 300 μm .

E10, when invagination of the optic vesicle has just begun, the *Pax2* and *Pax6* expression domains in the double mutants (Fig. 3B,D, respectively) are similar to those seen in wild type (Fig. 3A,C), although *Pax2* expression in the ventral optic stalk (brackets in Fig. 3A–D) is reduced relative to wild type (Fig. 3A,B), while *Pax6* expression is increased (Fig. 3C,D). By E11.5 in wild-type embryos, the *Pax2* and *Pax6* proteins have nearly assumed their mature expression profiles—*Pax6* in the retina and *Pax2* in the optic stalk—with a modest number of *Pax2*⁺ cells remaining in the ventral retina (Fig. 3E). At this same time, in the double mutants, however, nearly all of the ventral neuroepithelium is noticeably thickened, and nearly all of the cells of this thickened epithelium are both *Pax2*[−] and *Pax6*⁺ (Fig. 3F). The expansion of the ventral neuroepithelium (arrowheads in Fig. 3E,F), which is apparent even at E10 (Fig. 3A–D), prevents the normal ventralward extension of the RPE, and precludes closure of the optic disk. The RPE is largely confined to the dorsal aspect of the optic vesicle (Fig. 1J).

The thickened ventral region corresponds to the area of the neuroepithelium where *Vax1* and *Vax2* normally overlap in their expression from E9.5 to E11.5 (Fig. 2G–I; Ohsaki et al. 1999). It is marked by the pronounced up-regulation of proliferation, as assessed by a 2-h pulse of BrdU (Fig. 3G,H). This level of proliferation is aberrant for the astrocyte precursors of the optic stalk (boxed area

in Fig. 3G), but is normal for RPCs. At E12.5, the development of ventral retinal tissue extends all the way to the midline of the CNS—through what would be the ventral optic stalk in wild-type embryos—and all of these transformed cells now express *Pax6* mRNA (Fig. 3Q,R).


In contrast to the exuberant proliferation of neural retinal tissue, RPE differentiation is sharply limited in the *Vax* double mutants. Dopachrome tautomerase (*Dct*) mRNA, which encodes an enzyme required for melanin production in the RPE, is entirely confined to the dorsal aspect of the E12.5 optic cup (Fig. 3I,J). Similarly, *Mitf* (Microphthalmia-associated Transcription Factor), a protein that is associated with the onset and maintenance of pigmentation (Nakayama et al. 1998; Nguyen and Arnheiter 2000) and the early specification of the RPE (Bumsted and Barnstable 2000), is markedly reduced on the ventral side of the E11.5 optic cup of the double mutants and is absent by E12.5 (data not shown).

This morphological transformation of the developing optic stalk at the midpoint of mouse embryogenesis in the *Vax* double mutants is histologically similar to that seen in zebrafish embryos that have been exposed to *Vax* antisense morpholinos (Take-uchi et al. 2003). Although this antisense study focused on the morphogens that regulate *Vax* expression, and therefore did not include an examination of the battery of candidate target genes that we have analyzed, the histological appearance of the optic neuroepithelium in the morpholino-treated embryos nonetheless parallels that of the *Vax1/2* double mutants. The optic-stalk-to-retina transformation appears to be less extensive in the fish, but this may be attributed to the incomplete inactivation of the *Vax* genes by the morpholinos (Take-uchi et al. 2003). Thus, *Vax* control of mid-embryonic eye development, at least with respect to tissue morphogenesis, appears to be conserved between fish and mammals.

Ectopic induction of the transcription factor repertoire of RPCs

We find that the mid-embryonic transformation of optic stalk morphology is also accompanied by a marked alteration in the expression of genes that are normally controlled by *Pax2* and *Pax6*. By E12.5, cells in the ectopic retinal tissue of the ventral optic cup of the *Vax* double mutants have begun to express the full panoply of basic helix–loop–helix (bHLH) transcription factors that are activated by *Pax6*, and that are required for retinal neurogenesis and the differentiation of specific neuronal cell types (Reh and Levine 1998; Cepko 1999). These include *Math5* (Fig. 3M,N), *Neurog2* (data not shown), and *Neurod1* (Fig. 3O,P), which are required for the differentiation of retinal ganglion cells, photoreceptors, and amacrine cells, respectively (Perron et al. 1999; Wang et al. 2001; Inoue et al. 2002). None of these proteins are normally expressed in the optic stalk (Fig. 3M,O). Although it develops from a ventral anlage, the ectopic retina-like tissue that expresses these bHLH proteins nonetheless retains the ability to express dorsal retinal markers such as *Tbx5* (Fig. 3K,L; Koshiba-Takeuchi et al. 2000).

Figure 3. Histological and molecular transformation of optic stalk into retina in the *Vax* double mutants. (A,B) *Pax2* mRNA (brown reaction product) in the optic vesicle as it invaginates to form the optic cup, in wild-type (wt; A) and *Vax1/Vax2* double knockouts (dko; B). Dorsal is top, and midline is left. *Pax2* mRNA is expressed in the ventral optic stalk (vOS; bracketed), but its expression levels are slightly reduced in the double mutants, which display a thickened vOS. (C,D) *Pax6* mRNA (brown reaction product) at the same time, in wild-type (wt; C) and *Vax1/Vax2* double knockouts (dko; D). *Pax6* mRNA is expressed in the vOS (bracketed), but its expression levels are slightly elevated in the thickened vOS of the double mutants. (E,F) *Pax2* (green) and *Pax6* (red) protein expression in the nuclei of neuroepithelial cells of the E11.5 optic cup, as detected immunohistochemically in wild-type (wt; E) and *Vax1/Vax2* double knockout (dko; F) embryos. (G,H) BrdU⁺ nuclei of proliferative cells (light-blue signal), labeled with a 2-h pulse of BrdU, detected immunohistochemically in DV sections of wild-type (G) and double-mutant (H) E12.5 embryos. Developing optic tissue is outlined. A segment of what should be the vOS (boxed) is enlarged 2.5× in the insets. This segment contains a modest number of dividing cells in wild-type, but many more dividing cells in the double mutants. (I,J) Expression of Dopachrome tautomerase (*Dct*) mRNA, a marker of the RPE, as assessed by in situ hybridization (dark-field image) in DV sections of E12.5 wild-type (I) and *Vax* double-mutant (J) embryos. *Dct* expression is completely excluded from the ventral optic cup in the double mutants. (K,L) Expression of mRNA encoding the transcription factor *Tbx5*, a marker of the dorsal neural retina, in wild-type (K) and double mutants (L) at E12.5. (M,N) Expression of mRNA encoding the neurogenic bHLH protein *Math5* in wild-type (M) and double-mutant (N) embryos at E12.5. The optic disk (od, arrowhead) and optic stalk in wild-type are *Math5*⁻ (M), whereas much of the ectopic tissue produced in the double mutants is *Math5*⁺ (N). (O,P) Expression of *Neurod1* (*NeuroD*) mRNA in wild-type (O) and double-mutant (P) embryos at E12.5. The optic disk and optic stalk in wild-type are *Neurod1*⁻ (O), whereas much of the ectopic tissue produced in the double mutants is *Neurod1*⁺ (P). (Q,R) Expression of *Pax6* mRNA in wild-type (Q) and double-mutant (R) embryos at E12.5. All of the ectopic tissue produced in the double mutants is *Pax6*⁺ (R). (S,T) Expression of *sonic hedgehog* (*Shh*) mRNA in DV sections of wild-type (S) and *Vax* double-mutant (T) embryos at E10.5. *Shh* expression at both the telencephalic (top signal) and diencephalic (bottom signal) ventral midline is unaltered in the *Vax* double mutants. Bars in A (for A–D, I–L, S, T), E (for E, F), and M (for M–R) all represent 150 μm.



The rapid loss of ventral optic-stalk identity in the double mutants is not due to the loss of the primary ventralizing morphogen; sonic hedgehog levels remain high at the ventral midline in the double mutants (Fig. 3S,T), in contrast to the situation in *Foxg1* (*BF1*) mutants, where a portion of midline *Shh* expression is lost (Huh et al. 1999). This maintained expression of *Shh* is in keeping with the demonstration that the zebrafish *Vax* genes are downstream of *Shh* signaling and subject to *Shh* induction (Take-uchi et al. 2003).

Development of giant retinae

By late embryogenesis (E18.5) in the double mutants, the region that would normally be occupied by the optic nerve (Fig. 4A), is instead entirely replaced by doubled-over retinal tissue, which extends all the way to the mid-

line of the brain (Figs. 1L, 4B,C). In wild-type mice, RGC axons, which express the cell adhesion protein L1 (brown signal in Fig. 4A), are present in well-formed optic nerves, and cross the midline at the optic chiasm, near the ventral hypothalamus and behind the nasal turbinates. These optic nerve features are absent from the E18.5 double mutants. Instead, RGC axons run in two parallel streams that correspond to the inner surface of a duplicated (doubled-over) RGC layer, above which RGC axons normally course in the retina (Fig. 4B,C [black arrowheads in inset]), and these axons fail to cross the midline to form an optic chiasm (asterisk, Fig. 4B). This failure in midline crossing is a *Vax1* mutant phenotype (Bertuzzi et al. 1999; Hallonet et al. 1999), and is due to the loss of netrin-1 in the ventral midline cells that are normally *Vax1*⁺ (Bertuzzi et al. 1999). It is much more dramatic in the double mutants, because there is much more retina—and therefore many more RGCs and RGC




Figure 4. Complete transformation of optic nerve into retina in *Vax* double mutants. (A) DV section through the region of the optic nerves (on) and optic chiasm (oc) in a wild-type embryo at E18.5. The section has been stained with hematoxylin and eosin, and RGC axons have been immunostained with an antibody to the cell adhesion molecule L1 (brown reaction product). The optic nerves from the two eyes enter the base of the brain behind the nasal turbinates (nt) and cross the midline at the optic chiasm. (B) A section equivalent to that of A, but in the *Vax* double mutants. The optic nerves are replaced by doubled-over retina, a segment of which is boxed. Two tracts of RGC axons run along the RGC layer of the doubled-over retina, all the way to the base of the brain, where they pile up and fail to cross the midline (asterisk) or form an optic chiasm. (C) Continuation of the section in B, toward the left eye and lens. The boxed area is the same as that in B. (Inset) Enlargement of this segment illustrates the inverted and doubled-over retina. Duplicated RGC axon fiber tracts (black arrowheads) run along the inner surface of the RGC layers. The duplicated RPE layers (white arrowheads) face one another. (D) A section similar to that in C, hybridized with a probe to detect *Pax6* mRNA (pink signal). (E,F) Retinal sections at P7 immunostained for opsin, a photoreceptor marker, in wild-type (E) and double-mutant (F) retinas. (G,H) P7 retinal sections immunostained for neurofilament 160 (NF160), a horizontal cell marker, in wild-type (G) and double-mutant (H) retinas. (I,J) P7 retinal sections immunostained for glutamine synthase (GS), a Müller glial cell marker, in wild-type (I) and double-mutant (J) retinas. (K,L) P7 retinal sections immunostained for syntaxin, a marker of synapses within the inner plexiform layer, in wild-type (K) and double-mutant (L) retinas. Bars in A (for A–D) and E (for E–L) represent 100 μ m.

axons—in these mice than in the *Vax1* single mutants. At this point in retinogenesis (E18.5), *Pax6* expression normally becomes restricted to the RGC layer and the lower neuroblast layer, and this is also the case for the ectopic retina of the double mutants (Fig. 4D).

Most double mutants die at birth due to a cleft palate (asterisk in Fig. 4B), which is also a consequence of the loss of *Vax1* (Bertuzzi et al. 1999). However, in a small


fraction of the double-mutant mice (~6%), the palatal shelves partially fuse, and these mice remain viable for up to 3 wk after birth. We examined retinal cell-type specification at post-natal day 7 (P7) in these rare double-mutant individuals, since the mouse retina is not fully developed and laminated, with its full spectrum of cell types, until the end of the first post-natal week. Although the ectopic retina was always distorted and doubled over in the P7 double mutants (due to the impossibility of accommodating the very large amount of new retina within the very small confines of what should be the optic nerve), all major subgroups of retinal cell types, as assayed by the immunolocalization of marker genes, were nonetheless present in their normal location and lamination. These include photoreceptors, as visualized by rhodopsin (Fig. 4E,F), horizontal cells as visualized by neurofilament (NF)160 (Fig. 4G,H), and Müller glia as visualized by glutamine synthetase (Fig. 4I,J). A prominent lamination of synapses, as marked by syntaxin, is evident in the inner plexiform layer of both wild-type and double-mutant neonates (Fig. 4K,L). Thus, the optic stalk precursors of the double mutants are converted to RPCs that are capable of generating a well-differentiated and normally laminated post-natal retina.

Vax regulation of eye specification via *Pax6*

How is this conversion achieved? The complete formation of the presumptive optic stalk that we observe upon the loss of *Vax1* and *Vax2* indicates that these transcription factors normally act in concert to inhibit retinal specification. Among the most prominent drivers of retinal development, in both vertebrates and invertebrates, is the transcription factor *Pax6*. Loss-of-function mutations in the *Pax6* gene lead to the loss or reduction of retinal tissue, as for the *eyeless* mutant in *Drosophila* (Quiring et al. 1994), the *small eye* mutant in mice (Hill et al. 1991), and *aniridia* in man (Jordan et al. 1992). And conversely, gain-of-function misexpression of *Pax6* in a competent epithelium in both flies and vertebrates often leads to the production of ectopic eyes (Halder et al. 1995a,b; Chow et al. 1999).

Given that *Pax6* is rapidly acquired and *Pax2* is rapidly lost from the optic stalk in the double mutants (Fig. 3A–F), we looked for evidence of direct regulation of *Pax6* gene expression by *Vax1* and *Vax2*. Multiple *cis*-regulatory elements govern *Pax6* gene transcription (Fig. 5A), but early retinal expression of this gene is largely controlled by an enhancer element—designated the α -enhancer—which is located between exons 4 and 5 (Fig. 5A; Plaza et al. 1995; Kammandel et al. 1999; Marquardt et al. 2001). This enhancer contains binding sites for several transcription factors, including an autostimulatory *Pax6* site and an inhibitory *Pax2* site (Fig. 5A; Kammandel et al. 1999). Of particular importance to α -enhancer activity is an AT-rich region, designated DF4, which is immediately downstream of the *Pax2/6*-binding site apposed to the adjoining DF3 region (Fig. 5A; Plaza et al. 1995; Schwartz et al. 2000). This AT-rich sequence in

Figure 5. Vax binding to the *Pax6* gene. (A) Schematic structure of the mouse *Pax6* gene. Exons are numbered, and the positions of two alternative transcription start sites (P0, P1) and the initiator codon (ATG) are indicated. Two enhancer elements important for *Pax6* expression in the eye are indicated as follows: the ectodermal enhancer (ec; green boxes), whose 3' end contains elements critical for *Pax6* expression in the lens, and the retinal α -enhancer (α ; red boxes), which is located between exons 4 and 5, and which drives *Pax6* expression in the neural retina. Bottom line displays the nucleotide sequence of the central region of the α -enhancer, with a previously identified Pax2-binding site (blue) and a putative Vax-binding site (red) in the DF4 region. (Middle line) The arrowed fp and rp sites in the expanded boxes for the lens and α -enhancers represent the positions of the forward and reverse primers, respectively, that were used for the PCR reactions of ChIPs. (B) ChIP



of the Pax6 α -enhancer using Vax antibodies (see Materials and Methods). Chromatin from E10 heads from wild-type (wt), *Vax1*^{-/-}, *Vax2*^{-/-}, and *Vax1*^{-/-}*Vax2*^{-/-} mice was immunoprecipitated with preimmune rabbit IgG, Vax1, Vax2, Pax2, or Pax6 antibody, and then analyzed for precipitation of α -enhancer and lens-enhancer DNA sequences by PCR (see Materials and Methods). The positions of the PCR primers within the lens enhancer (fp1 and rp1) and the α -enhancer (fp2 and rp2) are indicated on the middle line in A. (Right panels) PCR bands of the appropriate size and sequence are detected for each ChIP PCR reaction that includes the putative Vax and Pax2/6-binding site of the Pax6 α -enhancer (fp2/rp2). (Right panels) The Pax6 α -enhancer was not detected in Vax1 or Vax2 ChIP DNA fragments from Vax double knock-outs, and Vax1 and Vax2 binding to the α -enhancer could not be detected in ChIPs performed from *Vax1* and *Vax2* mutants, respectively. (Left panels) No E10 Vax1, Vax2, or Pax2 ChIP products were detected with primers amplifying lens-enhancer sequences (fp1/rp1), whereas immunoprecipitation of these lens-enhancer sequences was readily detected with the Pax6 antibody. Preimmune rabbit IgG did not yield PCR bands for either the lens or the α -enhancer in any of the four genotypes tested. Chromosomal DNA of unfixed E10 embryonic heads was used for the PCR input lanes. (C) Electromobility shift assays (EMSA) demonstrating in vitro binding of Vax1 and Vax2 proteins to the Vax site depicted in A. EMSAs were performed with HA-tagged versions of Vax1 and Vax2 that were in vitro translated using reticulocyte lysates (Promega). Incubations with various wild-type and mutated DNA probes corresponding to the Vax-binding site of the α -enhancer DF4 region were performed as described in Materials and Methods. (Lanes 4,7,11,14) Both Vax1 and Vax2 (which carry identical homeodomains) shift the wild-type probe. Vax binding is not inhibited by preimmune IgG (lanes 5,8), but is inhibited by a monoclonal antibody against the HA tag (lanes 6,9). Vax1 and Vax2 binding are also competitively inhibited by 100-fold excess wild-type probe (lanes 12,15), but not by mutated probe (lanes 13,16).

DF4 binds a complex of (incompletely characterized) retinal proteins, and has been shown to be essential for α -enhancer activity (Plaza et al. 1995; Schwartz et al. 2000). It carries a putative Vax-binding site (J.W. Kim and G. Lemke, unpubl.) with a consensus homeodomain recognition motif (red sequence in Fig. 5A).

We first performed chromatin immunoprecipitations (ChIPs), using Vax1- and Vax2-specific antibodies that we have generated, and Vax-associated chromatin templates isolated from E10 embryonic mouse heads (Fig. 5B; see Materials and Methods). We performed these anti-Vax ChIP experiments in wild-type, *Vax1*^{-/-}, *Vax2*^{-/-}, and double-mutant embryos, and we also used anti-Pax2, anti-Pax-6, and nonimmune rabbit IgG for separate IPs. We used PCR primers to probe for endogenous transcription-factor binding both to the DF3/DF4 regions of the Pax6 retinal α -enhancer (primers fp2/rp2 in Fig. 5A,B), and also to the Pax6 lens enhancer (primers fp1/rp1). This latter element is located 5' of the upstream (P0) Pax6 transcription start site (Fig. 5A), contains a Pax6 autoregulatory site that is required for expression of Pax6 in the lens (Kammandel et al. 1999; Aota et al. 2003), and is not obviously regulated by either Vax1 or Vax2. We

were consistently able to identify and sequence verify the Pax6 α -enhancer in DNA recovered from anti-Vax1 ChIPs and then amplified by PCR with the fp2/rp2-flanking primers, using chromatin templates prepared from wild-type and *Vax2*^{-/-} E10 heads, but not from *Vax1*^{-/-} or double-mutant embryos (Fig. 5B, right). Similarly, we were able to detect Vax2 binding to this same retinal enhancer in ChIPs performed using chromatin from wild-type and *Vax1*^{-/-} embryos, but not from *Vax2*^{-/-} or double-mutant embryos. Using chromatin from E10 heads, a time at which both Pax2 and Pax6 are still well-expressed in the double mutants (Fig. 3B,D), we were able to detect binding of both of these transcription factors to the α -enhancer in all four genotypes. Conversely, we were unable to detect the binding of either Vax1, Vax2, Pax2, or Pax6 in mice of any genotype, to either the α - or the lens-enhancer, in ChIPs performed with the same chromatin templates, but using nonimmune (rabbit IgG) controls (Fig. 5B). We did not detect Vax1, Vax2, or Pax2 binding to the 5' lens-specific enhancer of the *Pax6* gene using these same templates and methods with the fp1/rp1 PCR primer set, but did detect Pax6 binding (Fig. 5B, left panels). Together, these results demonstrate

that Vax1 and Vax2 are specifically bound to the Pax6 α -enhancer in neuroepithelial cells of the E10 forebrain *in vivo*.

We next carried out a series of electromobility gel shift assays (EMSA) with hemagglutinin(HA)-tagged Vax1 and Vax2 proteins, prepared by coupled *in vitro* transcription and translation, and then incubated with a double-stranded DNA probe containing the AT-rich DF4 sequence of the α -enhancer that carries the putative Vax-binding site (Fig. 5C; see Materials and Methods). Both Vax1 and Vax2, which have identical homeodomains, specifically shift this probe (Fig. 5C, lanes 4,11,7,14, respectively). This mobility shift is competitively and specifically blocked both by excess wild-type but not mutated probe (Fig. 5C, lanes 12,13,15,16, respectively), and by incubation with an anti-HA monoclonal antibody but not by preimmune IgG (Fig. 5C, lanes 5,6,8,9, respectively).

We then performed a series of cotransfection experiments (Fig. 6A), using a panel of Vax1, Vax2, Pax2, and Pax6 expression constructs and an α -enhancer-driven β -galactosidase reporter (Kammandel et al. 1999), cotransfected into both 293T and COS7 cells. We found that reporter gene expression driven by the Pax6 α -enhancer is, as previously described, autostimulated (approximately fourfold) by coexpression of Pax6, and inhibited three- to fourfold by coexpression of Pax2 (Fig. 6A). Consistent with its expression in the Pax6⁻ cells of the optic stalk, Vax1 also repressed transcription driven by the Pax6 α -enhancer three- to fourfold. Vax2, whose mRNA overlaps with Pax6 in the ventral retina, exhibited more modest repression (Fig. 6A). When combined, Vax1 and Pax2 together exhibited a synergistic and extremely strong (~20-fold) repression of α -enhancer activity (Fig. 6A), consistent with their coexpression, with the fact that these two genes act in parallel to maintain the Pax6⁻ cells of the optic stalk (Bertuzzi et al. 1999; Hallonet et al. 1999), and with the close proximity of the Pax2- and Vax-binding sites in the Pax6 α -enhancer (Fig. 5A). The observation that mouse Vax1 and Vax2 exhibit repressor activity against the mouse Pax6 α -enhancer in

COS7 and 293T cells parallels the recent demonstration that chicken Vax exhibits repressor activity against the quail Pax6 α -enhancer upon transfection into quail neuroretina cells (Leconte et al. 2004).

Finally, we directly examined Vax regulation of Pax6 α -enhancer activity *in vivo*. We generated compound mutants that are both *Vax1*^{-/-}*Vax2*^{-/-} and also carry an α -enhancer-*taulacZ* (α - τ LZ) reporter gene (Baumer et al. 2003). We then assayed β -galactosidase activity histochemically (with X-gal), in sections of the eye from E12.5 compound mutant embryos (Fig. 6B). (The τ LZ reporter has β gal fused in-frame to the microtubule-associated protein tau, and results in the incorporation of the enzyme into microtubules.) In a normal embryo, α -enhancer activity becomes reduced and restricted after E11.5 (Marquardt et al. 2001). However, we find that the activity of this enhancer in the ectopic retinal tissue that develops in the *Vax1*^{-/-}*Vax2*^{-/-} α - τ LZ mice (dotted outline in Fig. 6B) is notably robust at E12.5, and that β gal is largely confined to the exuberant retina (Fig. 6B). Thus, the Pax6 retinal α -enhancer is dramatically activated in cells of the optic neuroepithelium in the absence of Vax1 and Vax2 *in vivo*.

Discussion

The vertebrate eye is among the most exquisitely polarized of sensory tissues, and its axial patterning—the specification of its dorsoventral and nasotemporal axes during development—is essential both to its topographic connection to the brain and to its mature function. Our results demonstrate that Vax1 and Vax2, transiently coexpressed from E9.5 to E11.5 at the junction between the optic stalk and the presumptive neural retina, are central to this process. Together, these two transcription factors cooperatively control eye-field polarization, neuroepithelial cell proliferation, and retinal differentiation.

These features of Vax function were not evident in either of the *Vax* single mutants. Optic stalk cells in *Vax1*^{-/-} mice, for example, fail to properly associate with RGC axons, and lose expression of Pax2 and acquire




Figure 6. Vax regulation of Pax6 gene expression. (A) Vax repression of the Pax6 α -enhancer. CMV-promoter-driven expression constructs for Vax1, Vax2, Pax2, and Pax6, in the indicated combinations, were cotransfected with a Pax6 α -enhancer-driven β -galactosidase reporter construct, into both HEK293 cells and COS7 cells, as described in Materials and Methods. Results displayed are for 293 cells; COS7 transfections yielded very similar results. Numbers below the graph indicate fold change in β gal activity relative to mock (empty expression vector)

control, in the absence or presence of cotransfected Pax6 (-/+Pax6). See text for details. (B) Activated expression of the Pax6 α -enhancer in the ectopic retinal tissue of the *Vax* double knockouts (*dko*). β -Galactosidase activity driven by the Pax6 α -enhancer, as coupled to the *taulacZ* (τ LZ) reporter gene (Baumer et al. 2003), was monitored *in vivo*, by X-gal staining of sections from *Vax1*^{-/-}*Vax2*^{-/-}*Pax6*- α - τ LZ embryos. Pax6- α - τ LZ expression is robust in the ectopic retinal tissue that develops in these mice (dotted outline). The boxed area in the left panel is enlarged 3x at right.

Pax6; however, they do not go on to differentiate into full-blown retina (Bertuzzi et al. 1999). Similarly, most *Vax2* mutants display histologically normal retinae and optic nerves. When analyzed during the second post-natal week, *Vax2*^{-/-} mice exhibit a dorsalization of the ventral retina in terms of both gene expression and the projection of RGC neurons to their targets in the superior colliculus (Mui et al. 2002), but this dorsalization is progressively less severe in progressively more nasal regions of the ventral retina; and essentially no dorsalization is evident in the extreme ventral nasal retina (Mui et al. 2002). One explanation put forward for this progressively diminishing penetrance along the nasal-temporal axis was that a second gene—graded similarly to and acting in concert with *Vax2*—might compensate for *Vax2* in the ventral nasal retina, where their combined expression was normally highest (Mui et al. 2002). Our results strongly support this possibility; they suggest that the second gene is *Vax1*, which acts not in the post-natal retina, when the *Vax2*^{-/-} RGC projection phenotype was analyzed, but rather at E9.5–E11.5, when the dorsoventral identity of the developing eye field is first established and consolidated (Fig. 2D–F). At the same time, our results suggest that the incomplete optic-nerve-to-retina transformation seen in the *Vax1* mutants is accounted for by the overlapping presence of *Vax2* from E9.5 to E11.5. This interpretation is consistent with the morphological and cell-tracing observations of Takeuchi and colleagues (2003) in zebrafish, where application of single *Vax1* or *Vax2* antisense morpholinos lead to modest changes in optic-stalk structure, but combined treatment with both antisense reagents induced the appearance of tissue that resembles retina histologically.

Shh is the dominant ventralizing signal in the developing eye field as it is elsewhere in the embryonic CNS; it patterns the field through induction of the *Pax2* gene proximally and the *Pax6* gene distally (Ekker et al. 1995; Macdonald et al. 1995). The undiminished expression of *Shh* in the *Vax* double mutants, along with presence of *Pax2* in the ventral optic stalk at E10.5, but not E12.5, together demonstrate that in the absence of *Vax*, *Shh* is sufficient for the induction, but not the maintenance of *Pax2*. Furthermore, the dramatic expansion of *Pax6* expression all the way to the CNS midline—the source of *Shh*—demonstrates that the normally more distal expression of the *Pax6* gene is not regulated simply by fixed lower levels of *Shh*. Instead, *Vax1* and *Vax2* act as intracellular effectors of sonic hedgehog in the developing eye field, and in their absence, neuroepithelial cells in the ventral-most structure of the field lose *Pax2* and acquire *Pax6*, assume the identity of cells in the next most dorsal structure, and become RPCs.

Our data suggest two mechanisms for *Vax* action in the establishment of ventral fate. These mechanisms are not mutually exclusive, and may operate in parallel. First, although the *Vax* proteins are clearly not required for the initial activation of the *Pax2* gene in the ventral optic stalk and retina (Fig. 3B), these proteins may nonetheless normally act to maintain expression of *Pax2*,

which, at midgestation, acts as a transcriptional repressor of the *Pax6* gene (Schwartz et al. 2000; Baumer et al. 2003). Second, our data indicate that the *Vax* proteins directly inhibit optic-stalk expression of *Pax6*, which acts as a dominant driver of retinal differentiation. The *Vax* and *Pax2* genes are coexpressed in the ventral optic primordium, both are induced by *Shh* (Schulte et al. 1999; Takeuchi et al. 2003), and misexpression of chicken *Vax* results in the expression of *Pax2* (Schulte et al. 1999; Barbieri et al. 2002).

In the *Vax* double mutants, *Pax2* expression is initiated as in wild type, but is rapidly lost, concomitant with an acquisition of *Pax6* and the subsequent activation of the retinal bHLH genes. The *Vax* proteins repress the *Pax6* gene in vitro (Fig. 6A; Leconte et al. 2004) and in vivo (Fig. 6B), especially when coexpressed with *Pax2* (Fig. 6A), and this effect is mediated at least in part by direct binding to the DF4 *Vax* site within the retinal enhancer of this gene (Figs. 5B,C, 6B). Our data suggest that the synergistic repression of the *Pax6* gene by *Vax1* and *Pax2* (Fig. 6A), which are normally coexpressed in the *Pax6*⁻ cells of the optic stalk, is mediated through this same α -enhancer, since the *Pax*- and *Vax*-binding sites of the enhancer are in close proximity (Fig. 5A). Although it is definitely possible that *Vax* proteins bind to other regions of the *Pax6* gene, our ChIP data indicate that the 5' lens enhancer is not one of them (Fig. 5B), and our compound mutant (β gal reporter) data suggest that the α -enhancer is a major target (Fig. 6B).

It should be noted that in vivo, the *Vax* genes in combination are far more potent than *Pax2* alone with respect to repression of the retinal differentiation program that is driven by *Pax6*. *Pax2* mutants in mice and zebrafish display an optic-nerve phenotype that is indistinguishable from the partially penetrant phenotype of the *Vax1* single mutants—they do not develop exuberant retina—and *Vax* gene expression is maintained in *Pax2*^{-/-} mice (Bertuzzi et al. 1999). Furthermore, the optic nerve phenotype that develops in *Vax1*^{-/-}*Pax2*^{-/-} double mutants is not obviously different from that of either single mutant (N. Baumer, pers. comm.). These observations favor a simple model in which the concerted loss of *Vax1* and *Vax2* leads to the abnormal expression of *Pax6* in the ventral optic stalk after E11.5, which in turn leads to the repression of *Pax2*, and the activation of the full program of bHLH-driven retinal differentiation.

One conundrum apparent from published expression analyses (Barbieri et al. 2002; Mui et al. 2002) is that the *Vax2* gene continues to be expressed in the ventral retina throughout late embryogenesis, in retinal ganglion cells that are also *Pax6*⁺. This would seem to be inconsistent with *Vax2* functioning as a repressor of the *Pax6* gene. As we will describe in detail elsewhere, this apparent inconsistency is resolved when the subcellular localization of the *Vax2* protein is examined in detail during embryonic and early post-natal eye development.

Taken together, the results presented above demonstrate that the *Vax* proteins cooperatively ventralize the developing eye field by acting at the midpoint of mouse

embryogenesis. They allow for the development of the optic nerve by inhibiting the development of the retina, and they achieve this through their ability to repress the *Pax6* gene and the retinal differentiation programs that it normally promotes.

Materials and Methods

Expression studies

In situ hybridization with ^{33}P -radiolabeled riboprobes was performed as described previously (Bertuzzi et al. 1999; Mui et al. 2002). Dissected mouse embryos were anesthetized and immersion fixed in 4% paraformaldehyde/PBS overnight at 4°C, followed by overnight infiltration with 20% sucrose. Cryoprotected tissues were then embedded in OCT medium (Miles). Hybridizations were performed with 20- μm coronal sections of retina at birth (P0), P7, and with embryos at E9.5–E13.5, and at E18.5.

Immunohistochemistry was performed with cryostat sections (20 μm) that were blocked with 10% normal goat serum prior to incubation with antibodies. The following antibodies were incubated overnight at 4°C: polyclonal mPax2 (Zymed, at 1:300), monoclonal mPax6 (DHSB, University of Iowa, at 1:10), polyclonal L1 (gift of Dr. Louis Reichardt, University of California, San Francisco, at 1:1000), monoclonal NF160 (Sigma, at 1:40), polyclonal Ph-H3 (Upstate, at 1:200), monoclonal rhodopsin (Chemicon, at 1:300), monoclonal syntaxin (Sigma, at 1:90), and polyclonal glutamine synthetase (Sigma, at 1:1000). FITC- and Cy3-conjugated goat anti-rabbit and goat anti-mouse antibodies (Jackson) were used at 1:200. Peroxidase-conjugated goat anti-rabbit antibodies (Jackson) were used at 1:100. Pax2 and Pax6 sections were counterstained with p-phenylenediamine dihydrochloride (Sigma); L1 sections were counterstained with hematoxylin and eosin.

Vax1 and Vax2 antibody production

Antibodies against mouse Vax1 (accession no. NP_033527) and mouse Vax2 (accession no. NP_036042) were generated against fusion proteins composed of the N-terminal fragment of Vax1 (residues 1–72) or Vax2 (residues 1–71) fused to glutathione-S-transferase (GST) in the pGEX-4T1 vector (Pharmacia) at the BamHI/XhoI sites. Polyclonal antibodies against recombinant GST-Vax1(1–72) or GST-Vax2(1–71) proteins were produced in rabbits by intradermal injection. Antibodies recognizing these fusion proteins were purified using the QuickPrep affinity purification kit (Sterogene Bioseparations), after prior binding to a GST affinity column, and were assessed for specificity by Western blot.

ChIP and PCR

In general, we followed the methods of Weinmann et al. (2001). Briefly, nuclei were isolated from E10 mouse heads, and chromatin was sheared into 0.5–1-kb fragments. Vax1, Vax2, Pax2, or Pax6 proteins and their associated protein–DNA complexes were isolated by immunoprecipitation with rabbit anti-Vax1 antibody, rabbit anti-Vax2 antibody, rabbit anti-Pax2 antibody, mouse anti-Pax6 antibody, or preimmune rabbit IgG (Vector). DNA fragments coprecipitated with Vax1, Vax2, Pax2, or Pax6 proteins were isolated by phenol/chloroform/isoamyl alcohol extraction, and 100 ng of these immunoprecipitated DNAs were used as templates for PCR amplification of the Pax6 lens en-

hancer (fp1/rp1) or the Pax6 α -enhancer (fp2/rp2) elements (see Fig. 5A,B). PCR was performed for 33 cycles, with 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C, after denaturation for 5 min at 94°C for each cycle. PCR products were cloned into pCRII-topo (Invitrogen Inc.) for automated sequencing. PCR primers for ChIP PCR were as follows: fp1, CTAAAGTAGACA CAGCCTT; fp2, GTGACAAGGCTGCCACAAGCGCC; rp1, GGAGACATTAGCTGAATTC; rp2, CCGTGTCTAGACAGA AGCCCTCTC

Electrophoretic mobility shift assays

Double-stranded wild-type oligomers (5' \rightarrow 3' strand, GACTTCCGCCTATTTCCAGAAAATTAAGCTCAAACCTTGA CGT) and mutant oligomers (5' \rightarrow 3' strand, GACTTCCGCC TATTTCCAGACCGGCAGCTCAAACCTTGACGT) containing the DF4 sequence of the Pax6 α -enhancer (Plaza et al. 1995; Kammandel et al. 1999) were labeled by exo(-) Klenow fragment in the presence of [α - ^{32}P]dCTP. ^{32}P -labeled oligomers were incubated with in vitro-translated protein samples in a binding buffer (10 mM HEPES at pH 7.7, 75 mM KCl, 2.5 mM MgCl₂, 0.1 mM EDTA, 1 mM DTT, 5% glycerol, 0.5% BSA, and 0.1 mg/mL poly-ddC) on ice for 30 min. Samples were analyzed by 5% polyacrylamide gel electrophoresis and autoradiography. For competition, ^{32}P -labeled oligomers were preincubated on ice for 10 min with 100 \times unlabeled wild-type oligomers or mutant DF4 oligomers.

Reporter analyses

The Pax6-408B/X construct of Kammandel et al. (1999) was cotransfected with pCMV-Pax6, pCMV-Pax2, pCS2(+)-MT-Vax1, or pCS2(+)-MT-Vax2 into 293T or COS7 cells. ptk-LUC was coexpressed as a normalization control for transfection efficiency. Cells were lysed in a buffer containing 25 mM Gly-Gly, 15 mM MgSO₄, 4 mM EGTA, 1% Triton-X 100, and 1 mM DTT, and β -galactosidase activity was assayed in luciferase equivalents of cell lysates.

X-gal staining

Vax1^{+/-}Vax2^{-/-} mice were bred with Pax6 α -taulacZ mice (Baumer et al. 2003) to generate Vax1^{+/-}Vax2^{-/-}Pax6- α -*rlz*^{+/-}E12.5 embryos. These were fixed with 0.5% glutaraldehyde/4% paraformaldehyde in PBS for 30 min on ice and cryoprotected in 20% sucrose/PBS overnight at 4°C. Sections from frozen embryos were washed three times with PBS, and stained in X-gal reaction solution: 35 mM potassium ferrocyanide, 35 mM potassium ferricyanide, 2 mM MgCl₂, 0.02% Nonidet P-40 (NP-40), 0.01% sodium deoxycholate, and 1 mg/mL X-gal.

BrdU labeling

Pregnant dams were pulsed with BrdU (100 $\mu\text{g/g}$ body w) injected intraperitoneally. The injection was repeated after 20 min, and the animals sacrificed and embryos collected 2 h after the first injection. Immunohistochemistry was performed with a mouse monoclonal anti-BrdU antibody (Sigma) diluted 1:100.

Acknowledgments

We thank Drs. Peter Gruss and Nicole Baumer for the generous provision of the *Pax6- α -rlz* mice and for continuing discussion, Joe Hash, Patrick Burrola, and Ramil Libat for excellent technical support, and Jamie Simon for the schematic drawings of

Figure 2. Supported by grants from the NIH (G.L.), the Telethon Foundation (S.B.) and the Italian Ministry of Research (S.B.); by a long-term fellowship from the Human Frontiers Science Program (J.W.K.); and by the Medical Scientist Training Program at University of California, San Diego (S.M.).

References

- Aota, S., Nakajima, N., Sakamoto, R., Watanabe, S., Ibaraki, N., and Okazaki, K. 2003. Pax6 autoregulation mediated by direct interaction of Pax6 protein with the head surface ectoderm-specific enhancer of the mouse Pax6 gene. *Dev. Biol.* **257**: 1–13.
- Barbieri, A., Broccoli, V., Bovolenta, P., Alfano, G., Marchitello, A., Mocchetti, C., Crippa, L., Bulfone, A., Marigo, V., Ballabio, A., et al. 2002. Vax2 inactivation in mouse determines alteration of the eye dorsal–ventral axis, misrouting the optic fibers and eye coloboma. *Development* **129**: 805–813.
- Baumer, N., Marquardt, T., Stoykova, A., Spieler, D., Treichel, D., Ashery-Padan, R., and Gruss, P. 2003. Retinal pigmented epithelium determination requires the redundant activities of Pax2 and Pax6. *Development* **130**: 2903–2915.
- Bertuzzi, S., Hindges, R., Mui, S.H., O’Leary, D.D.M., and Lemke, G. 1999. The homeodomain protein Vax1 is required for axon guidance and major tract formation in the developing forebrain. *Genes & Dev.* **13**: 3092–3105.
- Bumsted, K.M. and Barnstable, C.J. 2000. Dorsal retinal pigment epithelium differentiates as neural retina in the microphthalmia (mi/mi) mouse. *Invest. Ophthalmol. Vis. Sci.* **41**: 903–908.
- Cepko, C.L. 1999. The roles of intrinsic and extrinsic cues and bHLH genes in the determination of retinal cell fates. *Curr. Opin. Neurobiol.* **9**: 37–46.
- Chiang, C., Litingtung, Y., Lee, E., Young, K.E., Corden, J.L., Westphal, H., and Beachy, P.A. 1996. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. *Nature* **383**: 407–413.
- Chow, R.L. and Lang, R.L. 2001. Early eye development in vertebrates. *Ann. Rev. Cell. Dev. Biol.* **17**: 255–296.
- Chow, R.L., Altmann, C.R., Lang, R.A., and Hemmati-Brivanlou, A. 1999. Pax6 induces ectopic eyes in a vertebrate. *Development* **126**: 4213–4222.
- Ekker, S.C., Ungar, A.R., Greenstein, P., von Kessler, D.P., Porter, J.A., Moon, R.T., and Beachy, P.A. 1995. Patterning activities of vertebrate hedgehog proteins in the developing eye and brain. *Curr. Biol.* **5**: 944–955.
- Halder, G., Callaerts, P., and Gehring, W.J. 1995a. Induction of ectopic eyes by targeted expression of the eyeless gene in *Drosophila*. *Science* **267**: 1788–1792.
- . 1995b. New perspectives on eye evolution. *Curr. Opin. Genet. Dev.* **5**: 602–609.
- Hallonet, M., Hollemann, T., Pieler, T., and Gruss, P. 1999. Vax1, a novel homeobox-containing gene, directs development of the basal forebrain and visual system. *Genes & Dev.* **13**: 3106–3114.
- Hill, R.E., Favor, J., Hogan, B.L., Ton, C.C., Saunders, G.F., Hanson, I.M., Prosser, J., Jordan, T., Hastie, N.D., and van Heyningen, V. 1991. Mouse small eye results from mutations in a paired-like homeobox-containing gene. *Nature* **354**: 522–525.
- Huh, S., Hatini, V., Marcus, R.C., Li, S.C., and Lai, E. 1999. Dorsal–ventral patterning defects in the eye of BF-1-deficient mice associated with a restricted loss of Shh expression. *Dev. Biol.* **211**: 53–63.
- Inoue, T., Hojo, M., Bessho, Y., Tano, Y., Lee, J.E., and Kageyama, R. 2002. Math3 and NeuroD regulate amacrine cell fate specification in the retina. *Development* **129**: 831–842.
- Jordan, T., Hanson, I., Zaletayev, D., Hodgson, S., Prosser, J., Seawright, A., Hastie, N., and van Heyningen, V. 1992. The human PAX6 gene is mutated in two patients with aniridia. *Nat. Genet.* **1**: 328–332.
- Kammandel, B., Chowdhury, K., Stoykova, A., Aparicio, S., Brenner, S., and Gruss, P. 1999. Distinct cis-essential modules direct the time-space pattern of the Pax6 gene activity. *Dev. Biol.* **205**: 79–97.
- Koshiba-Takeuchi, K., Takeuchi, J.K., Matsumoto, K., Momose, T., Uno, K., Hoepker, V., Ogura, K., Takahashi, N., Nakamura, H., Yasuda, K., et al. 2000. Tbx5 and the retinotectum projection. *Science* **287**: 134–137.
- Lecointe, L., Lecoin, L., Martin, P., and Saule, S. 2004. Pax6 interacts with cVax and Tbx5 to establish the dorsoventral boundary of the developing eye. *J. Biol. Chem.* **279**: 47272–47277.
- Livesey, F.J. and Cepko, C.L. 2001. Vertebrate neural cell-fate determination: Lessons from the retina. *Trends Neurosci.* **2**: 109–118.
- Macdonald, R., Barth, K.A., Xu, Q., Holder, N., Mikkola, I., and Wilson, S.W. 1995. Midline signalling is required for Pax gene regulation and patterning of the eyes. *Development* **121**: 3267–3278.
- Marquardt, T., Ashery-Padan, R., Andrejewski, N., Scardigli, R., Guillemot, F., and Gruss, P. 2001. Pax6 is required for the multipotent state of retinal progenitor cells. *Cell* **105**: 43–55.
- Marti, E. and Bovolenta, P. 2002. Sonic hedgehog in CNS development: One signal, multiple outputs. *Trends Neurosci.* **25**: 89–96.
- Mi, H. and Barres, B.A. 1999. Purification and characterization of astrocyte precursor cells in the developing rat optic nerve. *J. Neurosci.* **19**: 1049–1061.
- Mui, S.H., Hindges, R., O’Leary, D.D.M., Lemke, G., and Bertuzzi, S. 2002. The homeodomain protein Vax2 patterns the dorsoventral and nasotemporal axes of the eye. *Development* **129**: 797–804.
- Nakayama, A., Nguyen, M., Chen, C., Opdecamp, K., Hodgkinson, C., and Arnheiter, H. 1998. Mutations in microphthalmia, the mouse homolog of the human deafness gene MITF, affect neuroepithelial and neural crest-derived melanocytes differently. *Mech. Dev.* **70**: 155–166.
- Nguyen, M.-T.T. and Arnheiter, H. 2000. Signaling and transcriptional regulation in early mammalian eye development: A link between FGF and MITF. *Development* **127**: 3581–3591.
- Ohkubo, Y., Chiang, C., and Rubenstein, J.L. 2002. Coordinate regulation and synergistic actions of BMP4, SHH and FGF8 in the rostral prosencephalon regulate morphogenesis of the telencephalic and optic vesicles. *Neuroscience* **111**: 1–17.
- Ohsaki, K., Morimitsu, T., Ishida, Y., Kominami, R., and Takahashi, N. 1999. Expression of the Vax family homeobox genes suggests multiple roles in eye development. *Genes to Cells* **4**: 267–276.
- Perron, M., Odecamp, K., Butler, K., Harris, W., and Bellefroid, E. 1999. X-ngnr-1 and Xath3 promote ectopic expression of sensory neuron markers in the nerula ectoderm and have distinct inducing properties in the retina. *Proc. Natl. Acad. Sci.* **96**: 14996–15001.
- Plaza, S., Dozier, C., Langlois, M.C., and Saule, S. 1995. Identification and characterization of a neuroretina-specific enhancer element in the quail Pax-6 (Pax-QNR) gene. *Mol. Cell. Biol.* **15**: 892–903.

- Quiring, R., Walldorf, U., Kloter, U., and Gehring, W.J. 1994. Homology of the eyeless gene of *Drosophila* to the Small eye gene in mice and Aniridia in humans. *Science* **265**: 785–789.
- Reh, T. and Levine, E. 1998. Multipotential stem cells and progenitors in the vertebrate retina. *J. Neurobiol.* **36**: 206–220.
- Schulte, D., Furukawa, T., Peters, M.A., Kozak, C.A., and Cepko, C.L. 1999. Misexpression of the Emx-related homeobox genes cVax and mVax2 ventralizes the retina and perturbs the retinotectal map. *Neuron* **24**: 541–553.
- Schwartz, M., Cecconi, F., Bernier, G., Andrejewski, N., Kammandel, B., Wagner, M., and Gruss, P. 2000. Spatial specification of mammalian eye territories by reciprocal transcriptional repression of Pax2 and Pax6. *Development* **127**: 4325–4334.
- Take-uchi, M., Clarke, J.D., and Wilson, S.W. 2003. Hedgehog signalling maintains the optic stalk–retinal interface through the regulation of Vax gene activity. *Development* **130**: 955–968.
- Wang, S.W., Kim, B.S., Ding, K., Wang, H., Sun, D., Johnson, R.L., Klein, W.H., and Gan, L. 2001. Requirement for math5 in the development of retinal ganglion cells. *Genes & Dev.* **15**: 24–29.
- Weinmann, A.S., Bartley, S.M., Zhang, T., Zhang, M.Q., and Farnham, P.J. 2001. Use of chromatin immunoprecipitation to clone novel E2F target promoters. *Mol. Cell. Biol.* **21**: 6820–6832.